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Abstract  
Background 
Patients increasingly benefit from immunosuppressive/immunomodulatory medications for a range of 
conditions allowing them a lifestyle similar to healthy individuals, including travel. However, the 
administration of live vaccines to immunodeficient patients bears the risk of replication of the 
attenuated vaccine microorganism. Therefore, live vaccines are generally contraindicated on 
immunosuppression. Data on live vaccinations on immunosuppressive/immunomodulatory medication 
are scarce. We identified all travellers seeking pre-travel advice in three Swiss travel clinics with a live 
vaccine during immunosuppressive/immunomodulatory therapy to ascertain experienced side effects. 
A retrospective and multicentre study design was chosen to increase the sample size. 
 
Methods 
This study was conducted in the travel clinics of the University of Zurich, the Swiss TPH, Basel, and 
Geneva University Hospitals. Travellers on immunosuppressive/immunomodulatory therapy who 
received live vaccines (yellow fever vaccination (YFV), measles/mumps/rubella (MMR), varicella 
and/ or oral typhoid vaccination (OTV)) between 2008 and 2015 were identified and interviewed. 
Sixty age-and sex-matched controls (matched to Basel/Zurich travel clinics travellers) were included. 
Results 
197 patients were identified. 116 patients (59%) and 60 controls were interviewed. YFV was 
administered 92 times, MMR 21 times, varicella four times and OTV six times to patients on 
immunosuppressive/immunomodulatory therapy. Most common medications were corticosteroids 
(n=45), mesalazine (n=28) and methotrexate (n=19). Live vaccines were also administered on 
biological treatment, e.g. TNF-alpha inhibitors (n=8). Systemic reactions were observed in 12.2% of 
the immunosuppressed vs. 13.3% of controls; local reactions in 7.8% of the immunosuppressed vs. 
11.7% of controls. In controls, all reactions were mild/moderate. In the immunosuppressed, 2/21 
severe reactions occurred: severe local pain on interferon-beta and severe muscle/joint pain on 
sulfasalazine. 
Conclusion 
Safety of live vaccines given to immunosuppressed patients cannot be concluded. However, it is re-
assuring that in the examined patient groups no serious side effects or infections by the attenuated 
vaccine strain occurred. 
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Introduction  
The use of immunosuppressive/immunomodulatory medications for a wide range of underlying 
conditions has been rising over the past years. Patients increasingly benefit from these therapies 
allowing them a lifestyle similar to healthy individuals, including travel to overseas destinations [1,2]. 
Travel destinations do not differ between patients on immunosuppressive therapy and other travellers, 
including trips to high-risk areas [2–4].  
Due to their immunosuppression, these patients are at higher risk to infectious diseases in term of 
infections, morbidity and mortality [5–9]. Consequently, immunisation is particularly important for 
this population.  
However, the administration of live vaccines, such as yellow fever vaccination (YFV), to 
immunodeficient patients bears the risk of replication of the attenuated vaccine microorganism and 
clinically manifest infection [10–12]. Therefore, most international guidelines state that live vaccines 
are contraindicated in patients on immunosuppression, leading to challenging conditions in every day 
consultations of this vulnerable group of patients [13–15]. Some national recommendations, such as 
the Finnish ones, allow live vaccinations on non-biological immunosuppression after careful 
risk/benefit assessment [16]. In Switzerland, the vaccination recommendations allow live vaccinations 
on low-dose methotrexate (MTX) [17–20]. All recommendations are mostly based on expert opinion, 
as data are scarce. These last few years, efforts were made to evaluate the safety of some live vaccines 
in selected and immunosuppressed individuals. In general, primary live vaccinations are potentially 
more dangerous than secondary vaccinations as the immune system cannot build upon an existing 
immune memory to deal with the attenuated vaccine strain. In contrast, a secondary live vaccine is 
believed to be safer as an immune memory response can be activated and avert a systemic infection.  
Measles, mumps, rubella vaccination 
Several studies on secondary measles, mumps, rubella (MMR) vaccinations have been published in 
patients with juvenile rheumatic diseases. Patients were on treatment with classical disease modifying 
antirheumatic drugs (DMARDs), such as MTX and/or biological therapy with tumour necrosis factor 
alpha (TNFα) blocking agents or interleukin 1 (IL1) receptor antagonists and vaccination was safe 
[21–23]. In a prospective study, 2/28 juvenile patients received a first-time MMR vaccination [24]. In 
one of them (therapy with MTX and corticosteroids) fever and a skin rash appeared 20 days post-
vaccination. It was concluded that the rash was part of the disease activity rather than a side effect of 
vaccination [personal communication]. Several studies reported on primary [25–27] and secondary 
[28] MMR vaccination in stable patients after solid organ transplantation (SOT). Only mild reactions 
were reported. Overall, studies in patients with autoimmune diseases and after SOT on low 
immunosuppressive therapies have shown no severe adverse events.  
		 5	
In some small studies, MMR vaccination was safely administered to children with leukaemia [29,30]. 
However, in a study published in 1962, a 2-year seronegative old boy with leukaemia on treatment 
with MTX (dosage not specified) was vaccinated against measles; he developed a pneumonia and died 
[31].   
Varicella 
In patients with rheumatic diseases on therapy with corticosteroids, DMARDs and/or TNFα blockers, 
two prospective studies were performed with a first-time varicella vaccination without safety issues 
[32,33]. Varicella vaccination was administered to 17 patients after kidney transplantation on therapy 
with prednisone, cyclosporine and azathioprine [34]. One patient developed a mild varicella rash. 
Several other smaller studies on varicella vaccination after SOT have been performed without any 
reported safety issues [26–28,35,36]. Most of the included patients had received a liver transplant; at 
the time of vaccination they had stable organ functions and were on low-dose immunosuppressive 
therapy [37].    
Yellow Fever vaccination 
So far, two studies have been published, in which YFV was administered to 87 patients with rheumatic 
diseases on therapy with DMARDs (incl. MTX) and biologicals [38,39]. No severe side effects 
occurred, but all vaccinations were secondary vaccinations; severe adverse events may not have 
emerged due to their rare frequency and the limited number of participants. In a retrospective study, 19 
patients received YFV while on treatment with a variety of medications after SOT [40]. Although 
17/19 vaccinations were primary YFV doses no important side effects were observed. In a cohort 
study, 19 patients on long-term low-dose or short-term high-dose corticosteroid treatment received a 
primary YFV; 15 were re-vaccinated. Apart from more local side effects, vaccination was safe [41]. 
Oral typhoid vaccination (OTV) 
OTV (Tya21) is believed to be safe. More than 400 million doses have been administered worldwide 
[personal communication] and no single occurrence of a systemic infection has been reported despite 
the administration to HIV patients [42]. However, data in patients with immunosuppressive agents are 
not available and is consequently contraindicated especially due to the availability of an inactivated 
parenteral vaccine. 
In this study we aim to add to the published scarce numbers on live vaccines in patients on 
immunosuppressive/immunomodulatory therapy by 
− Assessing how many individuals received live vaccines while on 
immunosuppressive/immunodulatory therapy in three of the largest Swiss Travel Clinics over a 5-
8-year time span 
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− Estimating the number of vaccine reactions in this group  
− Comparing reactions to live vaccines among travellers on therapy with 
immunosuppressive/immunodulatory medications to age-and sex matched healthy travellers who 
received the respective vaccination at a similar time point  
Rationale for study design 
A retrospective design was chosen as live vaccinations are contraindicated on most 
immunosuppressive/immunomodulatory therapies and are only allowed after a careful risk/benefit 
assessment. Thus, patients that fulfil the inclusion criteria are infrequent. A retrospective and 
multicentre study design was consequently chosen to increase the sample size. 
To overcome recall bias in the patient group we included an age-and sex matched control group of 
travellers without immunosuppressive/immunodulatory therapy who received the respective live 
vaccine in the same time period. 
For some medications, it is well accepted that live vaccines may be given; one example is long-term 
low-dose corticosteroid therapy. However, “low-dose” is defined differently from country to country, 
the threshold is fore example 20mg prednisone or equivalent in the USA, Switzerland and Germany 
vs. 10mg in France and the United Kingdom [43]. In the Netherlands the decision on whether live 
vaccines may be given is based on the cumulative prednisone dose. MTX is another example. The 
thresholds have been mainly based on expert opinion and lack solid data. For this reason, we decided 
to include also travellers vaccinated on low-dose corticosteroid therapy and other generally accepted 
medications. 
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Methods 
Study location and time frame 
This retrospective study was conducted in three Travel Clinics in Switzerland: the Travel Clinic 
(Zentrum für Reisemedizin, ZRM) at the Epidemiology, Biostatistics and Prevention Institute, 
University of Zurich, the Travel Clinic of the Swiss Tropical and Public Health Institute (Swiss TPH) 
in Basel and the Travel Clinic at the University Hospitals of Geneva (HUG). Pre-travel data forms 
filled between 2010 and 2015 (ZRM and Swiss TPH, HUG: 2008-2015) were retrospectively searched 
for live vaccinations administered during immunosuppressive/immunomodulating therapy. Ethics 
approval was obtained from the Zurich, Nordwestschweiz and Geneva Ethics committees (Reference 
numbers KEK-ZH 2013-0188, EKNZ 257/13, CCER 2016-00218). 
Data collection  
Before the travel consultation, all individuals completed a form (electronic at ZRM, paper format at 
Swiss TPH and HUG) including demographic information, details on the planned trip and data on their 
medical history including taken medications. Physicians verified the information during the 
consultation and added information on pre-existing medical conditions, used medications and 
prescribed vaccinations during the current consultation.   
As a first step, these forms were searched for all travellers on immunosuppressive/immunomodulatory 
medications (search terms in Box 1). In Basel and Geneva the search was performed manually. In 
Zurich, several collected data variables were searched electronically for the usage of an 
immunosuppressive/imunomodulatory medication. Amongst travellers detected by this search, those 
who received a live vaccine (MMR, varicella, YFV and/or OTV) were identified. Herpes Zoster 
vaccine was not available in Switzerland during the time period and thus could not be looked at in this 
study. 
The identified patients were contacted by telephone and asked the questions from a pilot-tested 
questionnaire. If the patients could not be reached by telephone they were contacted by E-Mail. The 
questionnaire was developed with the input from several European vaccination and travel medicine 
experts during meetings of the European Network for Tropical Medicine and Travel Health (TropNet) 
and consecutive post-meeting electronic correspondence. The following information was gathered: 
visit date, age, sex, types of received vaccinations, underlying condition(s) for 
immunosuppressive/immunomodulatory treatment, kind of immunosuppressive/immunomodulatory 
medication and dosage, time between the last dose of immunosuppressant before vaccination, 
reactions after the vaccination in the graduation mild (not interfering in daily activities), moderate 
(interfering with daily activities, but able to perform daily activities) and severe (not able to perform 
daily activities), serious adverse reactions (death, life-threatening, persistent or significant disability or 
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incapacity, hospitalisation or prolongation of existing inpatient hospitalisation, congenital anomaly or 
birth defect, other important medical event or reaction), actions taken due to vaccine reaction.  
While live vaccines are generally contraindicated under immunosuppressive therapy, “adequate” time 
intervals (between cessation of an immunosuppressive medication and the administration of a live 
vaccine) have been defined after which the administration of a live vaccine is considered safe. These 
time intervals differ between medications and depend on the drug’s half-life and other factors. 
“Adequate” time interval means a sufficient interval time between drug interruption and live vaccine 
immunisation, while the term “critical” time interval is used when a live vaccine was given before the 
“adequate” time interval had elapsed. L.G. Visser’s publication “The immunosuppressed Traveler” 
was used [44] as reference to define “adequate” time intervals. If the respective medication was not 
mentioned in the publication, the “adequate” time intervals as defined by the Swiss Federal Office of 
Public Health (FOPH) [18] were applied. In patients on corticosteroids, we differentiated between 
short-term (<2 weeks) and long-term (≥2weeks) use.  
In the following sections of this paper the term „immunosuppressive“ will include both 
„immunosuppressive and immunomodulatory” therapy. 
In Zurich and Basel, a healthy age and sex-matched control group was enrolled. For logistical reasons, 
in Geneva, the inclusion of controls was not feasible. Healthy controls (HC) had to fulfil the following 
inclusion criteria: no immunosuppressive therapy, sex- and age-matched, same live vaccination, the 
live vaccination was administered at the same time point (plus/minus six months), HCs were contacted 
in the same way as patients. Comparative analyses were performed between immunosuppressed 
patients in Basel/Zurich (BS/ZH immunosuppressed) vs. matched HCs. 
Statistical analysis 
Frequencies and percentages of categorical variables were compared using Chi-squared or Fisher’s 
exact tests as appropriate. Means, standard deviations (SD), medians and interquartile ranges (IQR) 
were reported and two-group comparisons were carried out using T-tests or Wilcoxon-Mann-Whitney 
tests as appropriate. All analyses were performed anonymously using Stata 13.1 (Stata Corp. LP, 
Texas, USA). 
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Results 
Across the three travel clinics, 197 travellers on immunosuppressive therapy received a live vaccine 
and 116 could be interviewed for the assessment of adverse reactions (Figure 1 - flow chart). Sixty 
non-immunosuppressed controls matched to the participants from the Basel and Zurich travel clinics 
were interviewed.  
Demographics 
Contacted immunosuppressed individuals were on a mean 45.3 years (SD 15.9) old and 57 (49.1%) 
were male. HCs had a comparable age (46.2 years, SD 15.4) and sex distribution (n=30 (50.8%) 
controls were male) to Basel/Zurich travel clinic patients (average 45.7 years, SD 15.4; 31 (51.7%) 
male. 
In the immunosuppressed patients the most common underlying diseases were rheumatic conditions 
(n=40, 34.5%) and inflammatory bowel diseases (n=33, 28.4%, Table 1).  
Overall, 92 vaccinations against yellow fever, 21 against MMR, four against varicella and six OTVs 
were given to patients on immunosuppression. None received a sole measles vaccination (Table 2). 
Controls received 48 YFVs, 14 MMR vaccinations, four OTVs and three varicella vaccinations.  
Percentages of participants who had previously received the respective administered live vaccination 
were comparable between immunosuppressed BS/ZH travellers and controls for YFV, mumps and 
rubella vaccines (data not shown). However 90.0% of controls had received a previous measles 
vaccinations compared to 41.7% of immunosuppressed BS/ZH patients (P=0.031). 
Most common medications across all immunosuppressed participants were corticosteroids (n=45). In 
all immunosuppressed travellers, the prednisone equivalent dosage was 7.5mg/day on a median, IQR 
5-20mg/day; for long-term (>2 weeks) use: 7.5mg/day, range: 1.25mg-80mg/day; and for short-term 
use (<2 weeks): 45mg a day, range: 5mg-840mg a day. Four patients (2 patients with 20mg/day, one 
50mg/day and one with 80mg/day) with long-term therapy were above the “permitted” maximum of 
≥20mg/day prednisone dose per day according to the Swiss vaccination recommendations [18]. 
The second most frequent drug was mesalazine (n=28), followed by MTX (n=19, weekly dose: 
median 12.5mg, IQR 10-20mg), with two patients treated with weekly MTX-dosages above 20mg, 
one with 22.5mg and one with 100mg. In the patient with a weekly dosage of 100mg, the last MTX-
intake was 4 days before re-vaccination against yellow fever. The other patient had received YFV 
outside the “critical” time interval.  
Live vaccines were also given on biological therapies, such as TNF-alpha inhibitors (n=8 travellers, 
Table 2). 
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All but five patients were on current immunosuppressive therapy (or in “critical time interval” after 
cessation/pausing of an immunosuppressive medication). In five travellers, adequate time intervals had 
elapsed since the last treatment dose was taken: One patient who received an MMR vaccine had taken 
the last MTX dose of 20mg 42 days before vaccination, two other individuals on MTX (20-25mg and 
5mg/week) received the YFV 91 and 106 days after the last dose was taken, another patient on 
ustekinumab received a YFV 143 days after the last dose; and one patient on 75mg 6-mercaptopurine 
therapy took the last dose 135 days before YFV.  
In BS/ZH immunosuppressed, on average, 0.6 (SD 0.7) inactivated vaccines were given at the time of 
live vaccine administration. In HCs, on average 0.9 (SD 1.0) inactivated vaccines were simultaneously 
administered (P=0.14).  
Safety assessment 
Overall, 22/116 (19.0%) of patients on immunosuppressive therapy reported reactions after the 
vaccination (Figure 2).  
Nine (7.8%) remembered local reactions, such as muscle pain or tension. Seven reactions were rated 
as mild; one patient with multiple sclerosis on interferon beta treatment reported a severe local 
reaction after a primary MMR vaccination. 
14/116 (12.2%) patients had systemic reactions: six (5.2%) had mild muscle and joint pain, four 
(3.5%) had flu-like symptoms, one of them with painful lymph nodes and nausea; two (1.7%) 
remembered fatigue, and one reported (0.9%) fever. Out of the systemic reactions, 11 were mild, two 
were moderate and one person with rheumatoid arthritis on treatment with sulfasalazine remembered 
severe muscle/joint pain after a primary YFV.  
Among HCs, 15/60 (25.0%) remembered reactions after the vaccination. 7/60 (11.7%) reported local 
reactions, such as muscle pain, haematoma or sensitive puncture. All local reactions were mild. 8/60 
(13.3%) HCs reported systemic side reactions; three (5.0%) remembered fatigue, one of them with 
fever. Two had (3.3%) flu-like symptoms and 4 (6.7%) had muscle/joint pain after the vaccination. 
Five systemic reactions were categorised as mild and two as moderate.  
There was no significant difference in percentages of local reactions and systemic reactions between 
controls and BS/ZH immunosuppressed (both P values=1.0). 
Likewise, severity of local and systemic reactions was comparable between the immunosuppressed 
and HCs. However, none of the HCs reported a severe reaction.  
No serious adverse event was reported. 
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In the five patients with “adequate time” intervals between cessation of immunosuppressive treatment 
and live vaccination, only one noticed mild muscle/joint pain. None of the five patients vaccinated in 
the “critical” time interval receiving long-term (≥2weeks) high-dose-corticosteroid treatment 
(≥20mg/day prednisone equivalent/day) or high-dose-MTX had side effects.  
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Discussion 
We conducted a retrospective study in immunosuppressed travellers who received a live vaccination in 
three Swiss Travel Centres. We identified 197 patients on immunosuppression who were vaccinated 
against YF, MMR, varicella or typhoid and 116 could be interviewed for assessment of experienced 
side effects. No serious reaction was reported. Local and systemic reactions occurred as frequently in a 
matched HC group (25.0%) as in the immunosuppressed (19.0%).  
Serious reactions due to live vaccines are extremely rare. It is estimated that a YEL-AVD (yellow 
fever vaccine-associated viscerotropic disease) occurs in 0.4 of 100.000 administered vaccine doses, 
with 1.0 per 100.000 doses in the >60-year olds and 2.3 per 100.000 administered doses in individuals 
aged ≥70 [45]. Thus our sample was too small to detect a severe case, particularly on a specific 
immunosuppressive regimen and vaccine, as immunosuppressive regimens were diverse.  
Moreover, according to the Swiss vaccination recommendations in patients with rheumatic diseases 
live vaccines are allowed on long-term (≥2weeks) low-dose corticosteroid (<20mg/day prednisone) 
non-systemic corticosteroid therapy, and methotrexate ≤20mg/week [18]. Short-term (<2 weeks) high-
dose-corticosteroid treatment (≥20mg/day prednisone equivalent/day) is usually permitted but some 
some experts will still wait two weeks or more before administering live vaccines [46]. As previously 
stated, because recommendations have been mainly based on expert opinion and lack solid data, we 
decided to include also travellers vaccinated on low-dose corticosteroid therapy and other generally 
accepted medications. 65.5% of all patients observed in our study might be considered to be on a weak 
immunosuppressive regimen (including budesonid, glatiramer acetate, interferon, mesalazine, 
sulfasalazine, long-term low-dose corticosteroid and short-term high-dose-corticosteroid treatment). 
No difference between high or weak immunosuppressive regimen was observed with regard to 
percentages of side effects, local reactions, systemic reactions and severity [data not shown]. 
Another limitation is the rapidly increasing diversity of immunosuppressive therapies, with the 
consequence that our study cannot be generalised to new medications. However, as severe reactions 
after live vaccinations may occur more often in the immunocompromised, the paucity of data on this 
topic makes us believe that even small sample size studies are important to be known by practitioners 
in travel medicine.  
Due to the retrospective study design, live vaccines were administered between 14 days and five years 
prior to the conducted interviews. Thus reduced recall on experienced vaccine reactions may have 
limited the obtained results. However, we believe that severe and serious reactions would have been 
recalled even after a five-year time span. We additionally tried to limit recall bias by contacting age-
and sex-matched HCs who had received the same vaccine during a similar time period. However, we 
cannot exclude that recall may differ in those with a pre-existing condition as they might have been 
more alert of vaccine reactions than healthy individuals. 
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Furthermore, it is possible that some vaccinees had very serious reactions, which may even have led to 
death, and thus could not be reached for an interview. Nevertheless, the safety division of Swissmedic 
has not detected a severe infection with a vaccine strain in an immunosuppressed patient between 
2001 and May 2016 [personal communication].  
On the other hand, the study can give some cautious data on effectiveness. No yellow fever case was 
reported in the Swiss population during the relevant time span, so we can be rather sure that none of 
the vaccinees was diagnosed with yellow fever. However, among measles cases reported in 
Switzerland, we do not know how many occurred in (vaccinated) immunosuppressed persons. 
Conclusion 
The decision on whether live vaccines can be given to immunosuppressed patients is a daily 
encountered challenge by specialists of varying backgrounds. In immunosuppressed patients, live-
attenuated vaccines can potentially be harmful if the vaccine strain reverts to the original pathogen and 
infects the vaccinated person. On the other hand these patients profit especially from these 
vaccinations as they are particularly vulnerable to vaccine-preventable infections [47–49]. Apart from 
infecting the immunosuppressed person, other vaccine-related local or systemic reactions are feared as 
well as re-activation of the underlying disease. 
By making our data on live vaccinations in immunosuppressed patients available to a wide audience 
our aim is to contribute to the currently scarce literature on this topic. From these additional data it is 
impossible to conclude that live vaccines can be safely given to immunosuppressed patients. However, 
despite the limitations discussed above it is re-assuring that in the examined patient groups serious 
side effects or infections by the attenuated vaccine strain did not occur. 
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